Charles J. Gonzalez

4.4k total citations · 3 hit papers
34 papers, 3.4k citations indexed

About

Charles J. Gonzalez is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Charles J. Gonzalez has authored 34 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 14 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Charles J. Gonzalez's work include HIV/AIDS Research and Interventions (16 papers), HIV/AIDS drug development and treatment (15 papers) and HIV Research and Treatment (13 papers). Charles J. Gonzalez is often cited by papers focused on HIV/AIDS Research and Interventions (16 papers), HIV/AIDS drug development and treatment (15 papers) and HIV Research and Treatment (13 papers). Charles J. Gonzalez collaborates with scholars based in United States, France and Spain. Charles J. Gonzalez's co-authors include John W. Mellors, Anne R. Meibohm, Jeffrey Chodakewitz, Fred Valentine, Joseph J. Eron, Douglas D. Richman, Diane V. Havlir, Deborah K. McMahon, Roy M. Gulick and Emilio A. Emini and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Charles J. Gonzalez

31 papers receiving 3.3k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

1997 1.5k citations Roy M. Gulick, John W. Mellors et al. New England Journal of Medicine profile →
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

2007 453 citations Beatriz Grinsztejn, Christine Katlama et al. profile →
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

2021 217 citations James M. Tesoriero, Charles J. Gonzalez et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles J. Gonzalez United States	18	2.6k	2.3k	658	348	311	34	3.4k
Richard M. Dunham United States	25	774 0.3×	1.4k 0.6×	872 1.3×	710 2.0×	356 1.1×	38	3.2k
Karen T. Tashima United States	35	3.7k 1.4×	2.7k 1.2×	983 1.5×	220 0.6×	2.0k 6.4×	110	5.2k
Cecilia M. Shikuma United States	35	2.3k 0.9×	2.0k 0.9×	959 1.5×	344 1.0×	1.8k 5.7×	156	4.2k
J. L. Fahey United States	37	725 0.3×	1.0k 0.4×	613 0.9×	522 1.5×	199 0.6×	99	3.8k
Jintanat Ananworanich Thailand	42	4.5k 1.7×	4.2k 1.8×	1.8k 2.7×	449 1.3×	1.7k 5.4×	285	6.7k
Ireneus P.M. Keet Netherlands	24	898 0.3×	1.7k 0.7×	568 0.9×	190 0.5×	183 0.6×	33	3.2k
Alex Lund Laursen Denmark	28	1.1k 0.4×	635 0.3×	1.0k 1.6×	171 0.5×	314 1.0×	125	2.5k
Seble Kassaye United States	24	1.3k 0.5×	505 0.2×	675 1.0×	131 0.4×	466 1.5×	135	2.1k
Eileen P. Scully United States	23	1.0k 0.4×	546 0.2×	440 0.7×	159 0.5×	168 0.5×	62	2.4k
Julie Elliott United States	27	968 0.4×	1.2k 0.5×	559 0.8×	231 0.7×	192 0.6×	58	2.3k

Countries citing papers authored by Charles J. Gonzalez

Since Specialization

Citations

This map shows the geographic impact of Charles J. Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles J. Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles J. Gonzalez more than expected).

Fields of papers citing papers by Charles J. Gonzalez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles J. Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles J. Gonzalez. The network helps show where Charles J. Gonzalez may publish in the future.

Co-authorship network of co-authors of Charles J. Gonzalez

This figure shows the co-authorship network connecting the top 25 collaborators of Charles J. Gonzalez. A scholar is included among the top collaborators of Charles J. Gonzalez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles J. Gonzalez. Charles J. Gonzalez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gonzalez, Charles J., et al.. (2024). Doxycycline post-exposure prophylaxis for preventing bacterial sexually transmitted infections (STIs): Are clinical providers supportive?. International Journal of STD & AIDS. 36(4). 297–303. 2 indexed citations

Rosenberg, Eli S., Vajeera Dorabawila, Rachel Hart-Malloy, et al.. (2023). Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection — New York, 2022. MMWR Morbidity and Mortality Weekly Report. 72(20). 559–563. 58 indexed citations

Rosenthal, Elizabeth M., Eli S. Rosenberg, Charles J. Gonzalez, et al.. (2022). Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State. PLoS ONE. 17(5). e0268978–e0268978. 12 indexed citations

O’Grady, Thomas, et al.. (2022). Evaluation of Trends in Preexposure Prophylaxis Prescriptions During the First 6 Months of the COVID-19 Pandemic in New York State. JAMA Network Open. 5(3). e224065–e224065. 4 indexed citations

Tesoriero, James M., et al.. (2022). Assessing the Impact of a PrEP Aware Week Campaign on PrEP Prescription Fills in NYS. Journal of Public Health Management and Practice. 28(5). 463–468. 4 indexed citations

Cunningham, Chinazo O., et al.. (2021). Substance Use Disorder Treatment in Pregnant Adults. 2 indexed citations

McGowan, Joseph P., et al.. (2021). Prevention and Management of Hepatitis A Virus in Adults With HIV. Europe PMC (PubMed Central). 1 indexed citations

Gonzalez, Charles J., et al.. (2012). Using Computer-Based Monitoring and Intervention to Prevent Harmful Combinations of Antiretroviral Drugs in the New York State AIDS Drug Assistance Program. The Joint Commission Journal on Quality and Patient Safety. 38(6). 269–276. 4 indexed citations

Gatell, José M., Christine Katlama, Beatriz Grinsztejn, et al.. (2010). Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(4). 456–463. 53 indexed citations

10.

Gabbay, Vilma, Rachel G. Klein, James S. Babb, et al.. (2009). A Preliminary Study of Cytokines in Suicidal and Nonsuicidal Adolescents with Major Depression. Journal of Child and Adolescent Psychopharmacology. 19(4). 423–430. 117 indexed citations

11.

Gabbay, Vilma, et al.. (2009). A cytokine study in children and adolescents with Tourette's disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 33(6). 967–971. 55 indexed citations

12.

Vogler, Mary, Hedy Teppler, Rebecca Gelman, et al.. (2004). Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248). JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(1). 576–587. 15 indexed citations

13.

Chien, Peter, Daniel Chen, Michael Tuen, et al.. (2004). HIV‐1–Infected Patients with Envelope‐Specific Lymphoproliferation or Long‐Term Nonprogression Lack Antibodies Suppressing Glycoprotein 120 Antigen Presentation. The Journal of Infectious Diseases. 189(5). 852–861. 6 indexed citations

14.

Gulick, Roy M., Anne R. Meibohm, Diane V. Havlir, et al.. (2003). Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 17(16). 2345–2349. 50 indexed citations

15.

Landay, Alan, Ellen S. Chan, John Spritzler, et al.. (2002). Evidence of Immune Reconstitution in Antiretroviral Drug-Experienced Patients with Advanced HIV Disease. AIDS Research and Human Retroviruses. 18(2). 95–102. 29 indexed citations

16.

Pérez‐Molina, José A., et al.. (2002). Differential characteristics of HIV-infected penitentiary patients and HIV-infected community patients. HIV Clinical Trials. 3(2). 139–147. 7 indexed citations

17.

Gulick, Roy M., John W. Mellors, Diane V. Havlir, et al.. (2000). 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine. Annals of Internal Medicine. 133(1). 35–39. 154 indexed citations

18.

Essajee, Shaffiq, Mimi Kim, Charles J. Gonzalez, et al.. (1999). Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 13(18). 2523–2532. 73 indexed citations

19.

Gulick, Roy M., John W. Mellors, Diane V. Havlir, et al.. (1997). Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. New England Journal of Medicine. 337(11). 734–739. 1531 indexed citations breakdown →

20.

Nardelli, Bernardetta, Charles J. Gonzalez, Martin T. Schechter, & Fred Valentine. (1995). CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells.. Proceedings of the National Academy of Sciences. 92(16). 7312–7316. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact